GlassScriptPhysician profile
Brooke N Hyde
NPI 1851959761
$5,081.56
in general payments reported to CMS, 2019-2025
30 companies · $1,029 in 2025
The $1,029 reported for 2025 was more than what 91% of Optometrist providers received nationally (typical 2025 total: $204).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $589 · 2020: $290 · 2021: $341 · 2022: $991 · 2023: $899 · 2024: $942 · 2025: $1,029.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,869.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,869.48 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sun Pharmaceutical Industries INC. | $570.77 | 2019-2024 | Cequa, Xelpros |
| Novartis Pharmaceuticals Corporation | $441.65 | 2019-2023 | |
| Bausch & Lomb Americas INC. | $429.95 | 2022-2025 | Miebo, Vyzulta, Xiidra |
| Allergan, INC. | $326.13 | 2019-2022 | |
| Apellis Pharmaceuticals, INC. | $300.81 | 2023-2025 | Syfovre |
| Tarsus Pharmaceuticals, INC. | $249.45 | 2024-2025 | Xdemvy |
| Abbvie INC. | $249.11 | 2023-2025 | |
| Harrow Eye, LLC | $244.23 | 2024-2025 | Vevye |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $236.35 | 2019-2021 | |
| Alcon Vision LLC | $228.91 | 2023-2025 | Tryptyr, Hydrus Microstent, Simbrinza |
| Oyster Point Pharma, INC. | $217.24 | 2022-2025 | Tyrvaya, Ryzumvi, Ryzumvi |
| Eyevance Pharmaceuticals LLC | $172.99 | 2022 | |
| Kala Pharmaceuticals, INC. | $157.41 | 2021 | |
| Biotissue Holdings INC. | $150.05 | 2022-2025 | |
| Astellas Pharma US INC | $147.89 | 2024-2025 | Izervay |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Regeneron Healthcare Solutions, INC. | $142.66 | 2023-2024 | Eylea Hd, Eylea |
| Sight Sciences, INC. | $140.54 | 2020 | |
| Johnson & Johnson Vision Care, INC. | $137.08 | 2022 | |
| Mallinckrodt Hospital Products INC. | $110.15 | 2020 | |
| Alimera Sciences, INC. | $105.35 | 2022-2024 | Yutiq, Iluvien |
| Dompe US, INC. | $89.39 | 2019 | |
| Ani Pharmaceuticals, INC. | $55.42 | 2025 | Purified Cortrophin Gel, Yutiq |
| Genentech USA, INC. | $44.79 | 2024 | Vabysmo |
| Aerie Pharmaceuticals, INC. | $22.97 | 2020 | |
| Eyepoint US, INC. | $22.29 | 2023 | |
| Glaukos Corporation | $20.96 | 2024 | Istent Trabecular Micro-Bypass System Model Is3 |
| Horizon Therapeutics Plc | $18.31 | 2022 | |
| Rayner Intraocular Lenses Limited | $17.06 | 2023 | Rayone Emv, Rayone Spheric, Rayone Aspheric |
| Thea Pharma INC. | $16.50 | 2024 | Iyuzeh |
| Amgen INC. | $15.15 | 2025 | Tepezza |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Brooke Hyde listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.